Why the study?
Does Wearable Cardioverter-Defibrillator (WCD) therapy improve outcomes in patients with suspected myocarditis?
Does Wearable Cardioverter-Defibrillator (WCD) therapy improve outcomes in patients with suspected myocarditis?
Wearable cardioverter-defibrillators may offer benefit in suspected myocarditis, highlighting the need for adequately powered randomized trials.
Answers are grounded in this paper and cite their sources.
May support WCD consideration in myocarditis but should not change practice; leaves open survival benefit pending powered RCTs.
Our data suggest that myocarditis patients may benefit from WCD therapy. However, as our study is not powered for outcome, further randomized studies powered for the outcome morbidity and mortality are necessary.
No takes yet. Share an insight, caveat, or question.
Blaschke et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: